Eugene

[email protected]

LATEST

Global Pharma Briefs: News from Europe, Asia and the US
By

By
A roundup of developments and latest news from Germany (Bayer, WuXi Biologics), South Korea (Avacta, Daewoong), and US (Hikma, ANI Pharmaceuticals). Germany Bayer, WuXi Biologics in Acquisition Agreement for Bayer’s…

California Governor Proposes State Generic Rx Drug Label
By

By
California’s Governor Gavin Newsom has proposed a new CalRx generic-drug program in his 2020–21 State Budget proposal that he submitted to California’s State Legislature, which would make California the first…

Alcami Sells Early-Stage API Facility; Covance Launches Cell/Gene Therapy Services
By

By
The latest news from CDMOs, CMOs, and suppliers featuring news from Alcami, Covance, WuXi Advanced Therapies, Comar, and Argonaut. Chemicals/Chemical API Manufacturing Alcami Sells API Mfg Facility in Netherlands to…

EMA Launches Joint Inspection Program for Sterile Drugs
By

By
The European Medicines Agency (EMA) and its European and international partners have launched a pilot program to increase their cooperation in the inspection of manufacturers of sterile medicines for human use.…

BI, Enleofen in $1 Bn-Plus Deal for Interleukin-11 Platform
By

By
Boehringer Ingelheim (BI) has acquired worldwide exclusive rights to the preclinical interleukin-11 (IL-11) platform of Enleofen Bio, a Singapore-based biopharmaceutical company, for developing therapies across a broad range of fibro-inflammatory…

Amag Pharmaceuticals’ CEO To Step Down; Conducts Strategic Review
By

By
Amag Pharmaceuticals, a pharmaceutical company specializing in women’s health, reports that its President and Chief Executive Officer (CEO), William Heiden, plans to step down. He will remain in his role…

Lilly To Acquire Skin Therapy Company Dermira for $1.1 Billion
By

By
Eli Lilly and Company has agreed to acquire Dermira, a biopharmaceutical company that develops new therapies for chronic skin conditions, for approximately $1.1 billion. Lilly says the acquisition will expand…

Incyte, MorphoSys in $2-Bn Licensing Deal for Cancer Drug
By

By
MorphoSys, a Martinsried, Germany-based biopharmaceutical company, and Incyte, a Wilmington, Delaware-based, global biopharmaceutical company, have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’ tafasitamab, a…

FDA Issues Complete Response Letter to Takeda for Investigational Therapy
By

By
Takeda Pharmaceutical has received a Complete Response Letter from the US Food and Drug Administration (FDA) in response to the submission of its biologics license application (BLA) for the approval…

WuXi STA, Colorcon Expand Mfg Capabilities, Colorcon Launches Platform
By

By
The latest news from CDMOs, CMOs, and suppliers featuring news from WuXi STA, Joinn Biologics, and Colorcon. Chemicals/Chemical API Manufacturing WuXi STA Opens Oligonucleotide Mfg Facility in China WuXi STA,…